Insulet Corporation Announces Proposed Initial Public Offering of Common Stock
BEDFORD, MA, April 30, 2007— Insulet Corporation (“Insulet”) announced today that it has filed a registration statement relating to its proposed underwritten initial public offering of 6,700,000 shares of its common stock. All shares in the offering will be sold by Insulet. Insulet also intends to grant to the underwriters an option to purchase up to 1,005,000 additional shares of its common stock to cover any over-allotments.
J.P. Morgan Securities Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated will serve as joint book-running managers, and Thomas Weisel Partners LLC and Leerink Swann & Co., Inc. will serve as co-managers for the proposed offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement.
Once available, a preliminary prospectus relating to these securities may be obtained by contacting one of the following:
J.P. Morgan Securities Inc., National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by calling (718) 242-8002.
Merrill Lynch, Pierce, Fenner & Smith Incorporated, World Financial Center, 250 Vesey Street, New York, NY 10080 or by calling (212) 449-1000.
About Insulet Corporation
Founded in 2000, Insulet Corporation is a medical device company located in Bedford, Massachusetts. The company seeks to improve the lives of people with diabetes and expand the use of continuous subcutaneous insulin infusion (CSII) therapy through innovative technology and feedback from people with diabetes and healthcare professionals. Insulet Corporation develops, manufactures and markets the OmniPod Insulin Management System, an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes.
For more information about Insulet Corporation and the OmniPod System, please visit our website at www.insulet.com.
Stephanie Marks for Insulet Corporation